Menu
1-702-720-6310 info@microcapspecualtors.com

Right To Try Act Could Benefit Biotech and Marijuana Companies.

A couple months back President Trump signed the Right to Try Act aimed at allowing terminally ill patients a right to try a drug that is not currently FDA approved.  This is a really promising development for innovative biotech drugs, as well as marijuana.  

A biotechnology company that we have discovered that could benefit from the “Right to Try Act” is PPCB (Propanc Biopharma, Inc.).  PPCB is currently preparing for its Phase 1 Clinical Trial of its lead product PRP, which was granted FDA Orphan Drug Designation for Pancreatic cancer.  If this is the first time you are hearing about PPCB, start doing our own research immediately.  PPCB is a very impressive small biotech firm, with an intriguing patent portfolio.  PPCB recently announced that it was selected to present at the 25th Annual NewsMakers in the biotech industry conference in New York City on September 7th, 2018.  This is a major conference for a small biotech firm like PPCB, and PPCB could receive significantly increased attention from the street in the coming weeks.  Those that find PPCB before the upcoming conference, and its upcoming clinical trial could be in store for a fun ride.  With a market cap of just hundreds of thousands PPCB is highly speculative, but for risk tolerant investors is a major find.    

Here are some other marijuana and biotech companies in the news:

Propanc Biopharma, Inc. (PPCB), Veristem (VSTM), CV Sciences, Inc. (CVSI), Canopy Growth Corporation (CGC) and Aurora Cannabis (ACBFF)

Propanc Biopharma, Inc. (PPCB)

Market Cap: $153K Share Price: $0.004

Propanc Biopharma Inc., a clinical stage biopharmaceutical company focusing on development of new treatments for cancer. Patients who have solid tumors such as pancreatic, ovarian and colorectal cancers will be the specific focus. Interestingly enough, this company will begin to experience trials with human subjects.  PRP is an FDA designated Orphan Drug, and is a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen administered by I.V injection. 

Propanc is currently readying for its first in-human study; and PRP aims to prevent tumor recurrence and metastasis from solid tumors. As it is commonly known, most all cancers are solid tumors, and metastasis is the main cause of patient death from cancer. Unfortunately, millions people died from cancer in 2012. A report by IMS Health states new therapies are causing the global oncology market to meet demand. This is expected to reach $150 billion by 2020. The Company’s focus patient populations are pancreatic, ovarian and colorectal cancers. This represents an estimated combined market segment of $14 billion in 2020, according to GBI Research. 

CV Sciences, Inc. (CVSI)

Market Cap: $591.1M Share Price: $6.52

CV Sciences (CVSI) has received more positive attention after it announced that it had appointed Joseph Maroon, MD, FACS to its Board of Directors. The Nevada-based company operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD, and a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors.

Canopy Growth Corporation (CGC)

Market Cap: $9.25B Share Price: $41.52

Constellation Brands announced a partnership with Canopy Growth back in October.  Investors benefited recently from the partnership as Constellation Brands pledged an additional $4 billion to their stake in the company.  This week through its wholly-owned subsidiary Tweed Inc., has been selected as an approved supplier by the Ontario Cannabis Store (“OCS”) to supply a wide variety of cannabis products through its online store starting October 17th, 2018.

Aurora Cannabis (ACBFF)

Market Cap: $5.87B Share Price: $6.12

Aurora Cannabis is receiving investor attention after announcing that its acquisition of Anandia Laboratories Inc. (“Anandia”) is now complete. The previously announced arrangement, under the provisions of the Business Corporations Act (British Columbia ), means that among other things, Aurora has now acquired all of the issued and outstanding shares of Anandia in an all-share transaction (the “Transaction”).

Anandia is a world-leading cannabis-focused science company, specialized in genomics, metabolite profiling, plant breeding, disease characterization, and cultivar certification, as well as providing testing services to producers and patient-cultivators.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two.  ACR Communication, LLC has been compensated one thousand dollars cash for this article and seventy-nine thousand two hundred dollars total by Regal Consulting, LLC, for PPCB.  PPCB and Regal Consulting, LLC were given an opportunity to edit information included in this article.  This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information.  ACR Communication, LLC, will not buy or sell any shares in stocks contained within this article for forty eight hours after this article’s distribution.  

For Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager

Email: info@microcapspecualtors.com

Phone: 1-702-720-6310

Country: United States

Website: http://microcapspeculators.com/

Search